Internal medicine journal
-
Internal medicine journal · Mar 2021
Real-world off-label use of icatibant for acute management of non-hereditary angioedema.
We retrospectively examined the indications and efficacy of off-label use of the bradykinin B2 receptor antagonist icatibant. The clinical heterogeneity, variability of response to icatibant and lack of efficacy of adrenaline described in this audit highlights both the need for biomarkers that can rapidly distinguish between histaminergic and non-histaminergic angioedema, and for guidelines to improve the utility of icatibant in the non-hereditary angioedema setting.
-
Internal medicine journal · Mar 2021
A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease.
Routine therapeutic drug monitoring (TDM) during treatment with anti-tumour necrosis factor (anti-TNF) agents in inflammatory bowel disease may increase treatment efficacy and cost-effectiveness, and reduce the risk of loss of response. ⋯ TDM was routinely used among inflammatory bowel disease gastroenterology clinicians who responded to this survey. However, interpretation of results and decision-making is variable, suggesting more guidance is required.
-
Internal medicine journal · Mar 2021
Observational StudyReduction of in-hospital cardiac arrest rates in intensive care-equipped New South Wales hospitals in association with implementation of Between the Flags rapid response system.
The NSW Clinical Excellence commission introduced the 'Between the Flags' programme, in response to the death of a young patient, as a system-wide approach for early detection and management of the deteriorating patient in all NSW hospitals. The impact of BTF implementation on the 35 larger hospitals with intensive care units (ICU) has not been reported previously. ⋯ The BTF programme was associated with a significant reduction in cardiac arrests in hospitals and ICU admissions secondary to cardiac arrests in 35 NSW hospitals with an ICU.
-
Internal medicine journal · Mar 2021
Silent suffering of the dying and their families: impact of COVID-19.
Death, grief and bereavement all look different in the current COVID-19 pandemic. Patients and families are suffering as a result of COVID-19 itself, and the measures required to contain it. As a result, health professionals need to be aware of potential for additional psychological distress, as well as the risk of prolonged grief disorder.
-
Internal medicine journal · Mar 2021
Mental health illness in chronic respiratory disease is associated with worse respiratory health and low engagement with non-pharmacological psychological interventions.
Patients with chronic respiratory disease commonly experience comorbid mental illness. This study aimed to explore associations between mental illness and respiratory health, as well as determine access to and uptake of mental health treatment. ⋯ Active treatment with psychotropic drugs was common; however, acceptance of non-pharmacological interventions was poor. Further research is required to understand co-existing mental illness management in chronic respiratory disease.